Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Zoetis Class Action Lawsuit Filed
Regulatory class action lawsuit

Zoetis Class Action Lawsuit Filed

Analysis based on 10 articles · First reported May 28, 2026 · Last updated May 31, 2026

Sentiment
-50
Attention
4
Articles
10
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Zoetis could lead to significant financial penalties and a decline in its stock price due to investor losses and reputational damage. The allegations regarding product performance and market share loss for Bedinvetmab, Sarolaner, Oclacitinib, and Lokivetmab may also impact investor confidence in Zoetis's future growth prospects.

Pharmaceuticals Legal Services
Event Summary

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Zoetis Inc. and certain of its officers, alleging violations of federal securities laws. The lawsuit claims that Zoetis made materially false and misleading statements regarding the growth, competitive positioning, market share, and veterinarian adoption of key products within its Companion Animal segment. Specifically, the complaint highlights weakening prescription growth for Bedinvetmab due to United States — Food and Drug Administration safety warnings, significant market share loss for Sarolaner to lower-priced competitors, and substantial market share loss for dermatology products Oclacitinib and Lokivetmab to newly launched treatments. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the lawsuit, with a deadline of July 27, 2026, to request lead plaintiff status. Peretz Bronstein and Nathan Miller of Bronstein, Gewirtz & Grossman, LLC are leading the efforts to recover damages for affected investors.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Zoetis
90 Zoetis made false statements
70 United States — Food and Drug Administration issued safety warnings Bedinvetmab
Entities Involved
stock
Zoetis
Zoetis is the defendant in a class action lawsuit alleging materially false and misleading statements regarding its Companion Animal segment products, which could lead to significant financial damages and reputational harm.
Importance 100 Sentiment -70
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm that filed the class action lawsuit against Zoetis, seeking to recover damages for investors. This event enhances their reputation as an investor-rights firm.
Importance 90 Sentiment 60
per
Peretz Bronstein
Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC and is actively involved in the class action lawsuit against Zoetis, aiming to restore investor capital.
Importance 70 Sentiment 50
per
Nathan Miller
Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting investors in joining the class action lawsuit against Zoetis.
Importance 60 Sentiment 40
oth
Bedinvetmab
Bedinvetmab, a canine pain treatment by Zoetis, is cited in the lawsuit for weakening prescription growth due to FDA safety warnings, contributing to the allegations against Zoetis.
Importance 50 Sentiment -40
oth
Sarolaner
Sarolaner, a canine parasiticide by Zoetis, is mentioned in the lawsuit for losing significant market share to competitors, impacting Zoetis's financial performance.
Importance 50 Sentiment -30
oth
Oclacitinib
Oclacitinib, a dermatology product by Zoetis, is losing substantial market share to a newly launched competing treatment, as alleged in the class action lawsuit.
Importance 50 Sentiment -30
oth
Lokivetmab
Lokivetmab, another dermatology product by Zoetis, is also losing substantial market share to a new competitor, contributing to the claims in the class action lawsuit.
Importance 50 Sentiment -30
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued safety warnings concerning Bedinvetmab, which contributed to the weakening prescription growth and is a key point in the lawsuit against Zoetis.
Importance 30 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.